GCP
MLTX icon

GSA Capital Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

GSA Capital Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Sell
80,233
-9,003
-10% -$149K 0.09% 284
2025
Q4 		$1.18M Buy
+89,236
New +$1.05M 0.1% 272
2024
Q4 		– Sell
-22,127
Closed -$1.12M – 1860
2024
Q3 		$1.12M Buy
22,127
+403
+2% +$18.9K 0.08% 406
2024
Q2 		$955K Buy
+21,724
New +$920K 0.07% 534

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's MLTX Position: Q1 2026 in Review

GSA Capital Partners reduced its MoonLake Immunotherapeutics (MLTX) stake by 10% in Q1 2026, selling an estimated $149K and leaving 80,233 shares worth $1.5M. The position accounts for 0.09% of the portfolio, ranked #284.

GSA Capital Partners first reported a position in MLTX in Q2 2024 and has held it in 4 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • GSA Capital Partners held 80,233 shares of MoonLake Immunotherapeutics worth $1.5M as of Q1 2026.
  • GSA Capital Partners sold 9,003 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $149K.
  • MoonLake Immunotherapeutics made up 0.09% of GSA Capital Partners's portfolio in Q1 2026, its #284 holding.
  • GSA Capital Partners first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 4 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.